PRX: Summary for PHARMACUTICAL CO - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:40am EST - Canadian Markets open in 2 hours and 50 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Par Pharmaceutical Companies Inc. (PRX)

On Feb 9: 24.07 USD 0.00 (0.00%)

MORE ON PRX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

PHARMACUTICAL CO (NYSE:PRX) Delayed quote data

Last Trade:	24.07 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	24.07
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	29.00

Day's Range:	N/A - N/A
52wk Range:	8.57 - 27.93
Volume:	0
Avg Vol (3m):	502,752
Market Cap:	838.09M
P/E (ttm):	21.55
EPS (ttm):	1.12
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add PRX to Portfolio

Download Data

HEADLINES

•	[video] Successfactors' Roller Coaster
	at Forbes.com (Fri, Feb 5)

•	UPDATE - Par Pharma unit says FDA declines nausea drug approval
	at Reuters (Fri, Feb 5)

•	Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
	PRNewswire (Fri, Feb 5)

•	Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2009 Results on February 24, 2010
	PRNewswire (Tue, Feb 2)

•	Improving Visibility on Watson
	Zacks.com (Wed, Jan 27)

•	3 Small Caps With Rocketing Shares
	at SmartMoney.com (Thu, Jan 14)

•	Watson Set to Beat Expectations
	Zacks.com (Thu, Jan 14)

•	The Put/Call Edge Plus 3 PowerRatings Stocks
	TradingMarkets.com (Wed, Jan 13)

•	Neutral on Watson
	Zacks.com (Fri, Jan 8)

•	Sector Snap: Generic drugmakers downgraded
	AP (Fri, Jan 8)

•	Time for U.K. Biotech to Scale Up -- or Die
	at The Wall Street Journal Online (Thu, Jan 7)

•	Neutral on Santarus
	Zacks.com (Wed, Jan 6)

•	MonoSol Rx and Strativa Pharmaceuticals Extend Strategic Relationship
	PRNewswire (Tue, Jan 5)

•	According To Credit Suisse Vice President, Certain Health Care Stocks To Benefit Greatly From U.S. Legislation: Which Companies Stand To Benefit The Most?
	Wall Street Transcript (Mon, Dec 21)

•	PAR PHARMACEUTICAL COMPANIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Fri, Dec 18)

More Headlines for PRX...

ANALYST

EPS Est (next year) (Dec-09) :	2.46
EPS Est (in 2 years) (Dec-10) :	1.70
Avg Rec (current)*:	2.2
PEG Ratio:	0.20

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•